A5045065420- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Arrhythmias and Treatments
- Lipoproteins and Cardiovascular Health
- Systemic Lupus Erythematosus Research
- COVID-19 Clinical Research Studies
- Health Systems, Economic Evaluations, Quality of Life
- Blood Coagulation and Thrombosis Mechanisms
- Blood Pressure and Hypertension Studies
- Cardiac Imaging and Diagnostics
- Cardiac tumors and thrombi
- Peripheral Artery Disease Management
- Long-Term Effects of COVID-19
- Cardiac electrophysiology and arrhythmias
- Cardiac Valve Diseases and Treatments
- Liver Disease Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Atherosclerosis and Cardiovascular Diseases
- Infective Endocarditis Diagnosis and Management
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiovascular Function and Risk Factors
- Platelet Disorders and Treatments
- Acute Myocardial Infarction Research
- Sepsis Diagnosis and Treatment
Sapienza University of Rome
2016-2025
Policlinico Umberto I
2018-2023
The Patients Association
2022
University of Perugia
2020
Magna Graecia University
2017
Gut microbiota is emerging as a novel risk factor for atherothrombosis, but the predictive role of gut-derived lipopolysaccharide (LPS) unknown. We analyzed (1) association between LPS and major adverse cardiovascular events (MACE) in atrial fibrillation (AF) (2) its relationship with adherence to Mediterranean diet (Med-diet).
Background The number of patients with atrial fibrillation (AF) and cancer is rapidly increasing in clinical practice. impact on outcomes this patient population unclear, as the performance HAS‐BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol) CHA 2 DS ‐VASc (Congestive Heart Failure, Hypertension, Age ≥ 75 years, Diabetes Mellitus, Stroke Transient Ischemic Attack, Vascular Disease, 65 to 74 Years, Sex...
Abstract Although direct oral anticoagulants (DOACs) are non-inferior to Vitamin K antagonists (VKA) in preventing ischemic stroke (IS) atrial fibrillation (AF) patients, there limited data regarding severity and prognosis of patients admitted with IS during DOAC treatment. We performed a single center retrospective study including AF on the Emergency Department for were included. The primary endpoint was analyse evaluated through NIHSS scale according anticoagulant therapy. secondary...
Background Experimental studies demonstrated that glutathione peroxidase 3 ( GP x3), an antioxidant enzyme catabolizes hydrogen peroxide, protects against thrombosis. Little is known about its role in cardiovascular disease. Methods and Results A prospective cohort study was conducted 909 atrial fibrillation patients. Serum activities of x3, superoxide dismutase SOD ), catalase were measured at baseline to assess the risk events during a mean follow‐up 43.4 months (3291 person‐years). Nox2...
To investigate the decline of estimated glomerular filtration rate (eGFR) in patients with atrial fibrillation (AF) treated vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs).Multicentre prospective cohort study including 1667 nonvalvular AF. The eGFR was assessed by CKD-EPI formula at baseline and during follow-up. primary endpoint median annual according to VKA (n = 743) NOAC 924) use. As secondary endpoints, we analysed transition <50 mL/min/1.73 m2 class worsening.Median...
Atrial fibrillation (AF) has multiple cardio-metabolic comorbidities, including obesity. The use of direct oral anticoagulants (DOACs) in patients with AF and obesity is still uncertain owing to the concern possible ineffective DOAC plasma concentration. We evaluated peak trough concentrations DOACs different degrees Observational single-center study AF, between April 2022 2024. Obesity was defined as body mass index (BMI) ≥ 30.0 kg/m2. 2-hour were assessed. Intake verified on site....
Optimal duration of anticoagulant therapy for left ventricular thrombous (LVT) is unclear. The aim this study to evaluate effectiveness and safety vitamin K antagonists (VKAs) up 12 months in patients with LVT. Patients diagnosed LVT between 2011 2023 treated VKAs until resolution or were enrolled a retrospective cohort study. Primary outcome included on-treatment resolution, secondary outcomes acute ischemic stroke, myocardial infarction, peripheral embolism, major clinically relevant...
Not applicable